- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Oncoinvent ASA: BerGenBio and Oncoinvent - Key Dates for Completion of Merger | 5 | Oslo Børs | ||
| ONCOINVENT Aktie jetzt für 0€ handeln | |||||
| Fr | BERGENBIO ASA: BerGenBio and Oncoinvent - Key Dates for Completion of Merger | 2 | Cision News | ||
| 20.10. | Oncoinvent ASA: Financial calendar | 1 | Oslo Børs | ||
| 08.10. | Oncoinvent meldet vielversprechende Studienergebnisse für Krebstherapie Radspherin | 1 | Investing.com Deutsch | ||
| 08.10. | Oncoinvent reports promising results for cancer treatment Radspherin | 1 | Investing.com | ||
| 08.10. | Oncoinvent AS: Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin to Treat Ovarian Cancer | 228 | PR Newswire | New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression
OSLO, Norway, Oct. 8, 2025 /PRNewswire/ -- Oncoinvent ASA, a clinical-stage... ► Artikel lesen | |
| 29.08. | Thor Medical To Supply Thorium-228 For Oncoinvent's Phase 3 Radspherin Program | 3 | RTTNews | ||
| 29.08. | ONCOINVENT AS: Thor Medical and Oncoinvent Enter Strategic Thorium-228 Supply Agreement | 4 | Cision News | ||
| 27.08. | Oncoinvent im Q2 2025: Umsatzsprung und erfolgreiche Kostensenkungen | - | Investing.com Deutsch | ||
| 27.08. | Oncoinvent advances phase 2 ovarian cancer trial, reports positive data | 3 | Investing.com | ||
| 27.08. | Oncoinvent: Starke Studiendaten und verbesserte Finanzlage ebnen Weg für Fusion | 2 | Investing.com Deutsch | ||
| 27.08. | Oncoinvent H1 2025 slides reveal strong clinical data and improved financials | 2 | Investing.com | ||
| 27.08. | Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer | 329 | PR Newswire | OSLO, Norway, Aug. 27, 2025 /PRNewswire/ -- Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing... ► Artikel lesen | |
| 22.08. | Oncoinvent ASA invites to a webcast presentation of 1H 2025 on Wednesday 27 August 2025 | 1 | Oslo Børs | ||
| 04.08. | Oncoinvent ASA: Oncoinvent shareholders approve the merger plan with BerGenBio | - | Oslo Børs | ||
| 03.07. | Oncoinvent ASA: Notice of Extraordinary General Meeting | - | Oslo Børs | ||
| 01.07. | BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent | 1 | FierceBiotech | ||
| 30.06. | Oncoinvent AS: Announcement of fully underwritten rights issue | 607 | PR Newswire | OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA the ("Company") hereby announces a fully underwritten rights issue with preferential subscription rights (the "Subscription Rights")... ► Artikel lesen | |
| 30.06. | Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue | 346 | PR Newswire | OSLO, Norway, June 30, 2025 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a... ► Artikel lesen | |
| 18.06. | Oncoinvent ASA: Oncoinvent: Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases | 1 | Oslo Børs |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,97 | 0,00 % | Novartis kündigt die milliardenschwere Übernahme von Avidity Biosciences an, um damit das eigene Portfolio zu stärken | Bereits im Sommer wurde darüber gemunkelt, nun gibt es auch Gewissheit: Novartis übernimmt das US-Biotechunternehmen Avidity Biosciences und greift dafür tief in die Tasche. Zwölf Milliarden US-Dollar... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,290 | 0,00 % | Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings | ||
| DYNE THERAPEUTICS | 24,170 | 0,00 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| MAPLIGHT THERAPEUTICS | 18,050 | 0,00 % | MapLight Therapeutics Prices IPO Of 14.75 Mln Shares At $17.00/shr | WASHINGTON (dpa-AFX) - MapLight Therapeutics Inc., a clinical-stage biopharmaceutical company focused on
improving the lives of patients suffering from debilitating central nervous
system... ► Artikel lesen | |
| NUVALENT | 97,95 | +4,88 % | Piper Sandler erhöht Kursziel für Nuvalent auf 128 US-Dollar wegen ALK-Potenzial | ||
| BEAM THERAPEUTICS | 26,710 | 0,00 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 186,82 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 58,53 | 0,00 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ZENAS BIOPHARMA | 31,500 | 0,00 % | Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis | - Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - WALTHAM, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Zenas... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 19,470 | 0,00 % | Summit Therapeutics: A Risky Bet in the Biotech Arena? | ||
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 21,420 | 0,00 % | Immunovant Inc.: Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 | ||
| VENTYX BIOSCIENCES | 6,460 | 0,00 % | Ventyx Biosciences: NBC feiert Daten-Knall und +928% in 6 Monaten | Der Party-Herbst reißt nicht ab: Nach dem Tenbagger Minerva explodieren im No Brainer Club die nächsten Kurs-Granaten. Eine davon ist die Aktie von Ventyx Biosciences. Die Ventyx-Aktie hatte der No... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,210 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib | Detailed results from bezuclastinib's positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this... ► Artikel lesen |
ONCOINVENT ASA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,04 % bei einem Aktienkurs von 0,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONCOINVENT ASA finden Sie auf Wallstreet Online.